8 Results for "

neuroendocrine carcinoma

" in MedChemExpress (MCE) Product Catalog:
Products (8)

8 Results for "neuroendocrine carcinoma" in MCE Product Catalog:

4
4 Cited Publications
Cat. No.: HY-10332
CAS No.: 194413-58-6
Synonyms: (Z)-SU5416
Target:  

VEGFR

(Z)-Semaxanib ((Z)-SU5416) is a VEGF receptor tyrosine kinase inhibitor that blocks VEGF signaling through Flk-1/KDR. (Z)-Semaxanib inhibits angiogenesis by preventing new blood vessel formation. (Z)-Semaxanib induces cytotoxicity in liver cancer cells. (Z)-Semaxanib can be used in research on metastatic renal cell carcinoma, gastrointestinal stromal tumors, well-differentiated pancreatic neuroendocrine tumors, and solid tumors .
loading...
    loading...
Cat. No.: HY-P9978
CAS No.: 1924598-82-2
Synonyms: JS-001; TAB-001; Tripleitriumab; CHS-007; Teriprizumab; Treprizumab
Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma .
loading...
    loading...
Cat. No.: HY-P991731
Synonyms: ZG006
Target:  

CD3 Notch

Research Areas:  

Neurological Disease Cancer

Alveltamig (ZG006) is a trispecific T cell engager targeting Delta-like ligand 3 (DLL3)/CD3, mediating T cell-specific killing of DLL3-expressing tumor cells. Alveltamig can be used for the researches of small cell lung cancer and neuroendocrine carcinoma .
loading...
    loading...
Cat. No.: HY-P9972
CAS No.: 1935694-88-4
Synonyms: PDR001

Target:  

PD-1/PD-L1 IFNAR

Research Areas:  

Cancer

Spartalizumab is a humanized PD-1 IgG4 monoclonal antibody, with a Kd of 0.83 nM for human PD-1 and a Kd of 0.93 nM for cynomolgus monkey PD-1. Spartalizumab binds to PD-1 and blocks its interaction with the ligands PD-L1 and PD-L2. Spartalizumab induces increased IFNγ release. Spartalizumab can be used in the research of anaplastic thyroid carcinoma (ATC) and neuroendocrine neoplasms (NENs) .
loading...
    loading...
Cat. No.: HY-115590
CAS No.: 1902983-63-4
Research Areas:  

Cancer

JP-11646 is a pan-PIM inhibitor with increased potency against PIM2 (IC50 = 0.5 nM). JP11646 is freely reversible and ATP non-competitive. JP-11646 results in a decrease of PIM1, 2, and 3 mRNA. JP-11646 can effectively inhibit cell viability in small cell lung cancer (SCLC) and large cell neuroendocrine carcinomas of the lung (LCNEC). JP-11646 can cause a decrease in p-4EBP-1 protein, increasing the cleavage of caspases while decreasing caspase-3. JP-11646 induces apoptosis or necroptosis in cells. JP-11646 leads to reductions in MYC paralogs. JP-11646 can be used for the study of SCLC, LCNEC, human acute leukemia (AML), multiple myeloma (MM), and triple-negative breast cancer (TNBC) .
loading...
    loading...
Cat. No.: HY-W591818
CAS No.: 452105-33-8
Target:  

Drug Derivative

Research Areas:  

Cancer

Sunitinib carboxylic acid is a carboxylic acid metabolite of Sunitinib (HY-10255A). Sunitinib is a multi-target tyrosine kinase inhibitor, mainly used to inhibit malignant tumors such as gastrointestinal stromal tumors, renal cell carcinoma, and pancreatic neuroendocrine tumors .
loading...
    loading...
Cat. No.: HY-P9978S
Research Areas:  

Cancer

15N-Labeled Toripalimab is the 15N-labeled Toripalimab (HY-P9978). Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma.
loading...
    loading...
Cat. No.: HY-P992148
CAS No.: 3058592-86-9
Synonyms: ZL-1310 Antibody
Target:  

Notch ADC Antibodies

Research Areas:  

Cancer

Zocilurtatug (ZL-1310 Antibody) is a human monoclonal antibody targeting DLL3. Zocilurtatug serves as the targeting antibody component of antibody-drug conjugates (ADCs) and is used in research related to small cell lung cancer and neuroendocrine carcinoma. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
loading...
    loading...